june hancock mesothelioma research fundEstimated Valuation
£23k
Pomanda estimates the enterprise value of JUNE HANCOCK MESOTHELIOMA RESEARCH FUND at £23k based on a Turnover of £49.1k and 0.47x industry multiple (adjusted for size and gross margin).
june hancock mesothelioma research fundEstimated Valuation
£155.8k
Pomanda estimates the enterprise value of JUNE HANCOCK MESOTHELIOMA RESEARCH FUND at £155.8k based on an EBITDA of £43.9k and a 3.55x industry multiple (adjusted for size and gross margin).
june hancock mesothelioma research fundEstimated Valuation
£622k
Pomanda estimates the enterprise value of JUNE HANCOCK MESOTHELIOMA RESEARCH FUND at £622k based on Net Assets of £278.7k and 2.23x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
June Hancock Mesothelioma Research FundOverview
June Hancock Mesothelioma Research Fund is a live company located in sheffield, S3 8DT with a Companies House number of 06249601. It operates in the other human health activities sector, SIC Code 86900. Founded in May 2007, it's largest shareholder is
unknown.
June Hancock Mesothelioma Research Fund is a established,
micro sized company, Pomanda has estimated its turnover at
£49.1k with
declining
growth in recent years.
June Hancock Mesothelioma Research Fund Health Check
Pomanda's financial health check has awarded June Hancock Mesothelioma Research Fund a 2.5 rating. We use a traffic light system to show it exceeds the industry average on 1 measures and has 4 areas for improvement. Company Health Check FAQs
Health Rating2.5out of 5
1 Strong
3 Regular
4 Weak
Size
annual sales of £49.1k, make it smaller than the average company (£696.4k)
£49.1k - June Hancock Mesothelioma Research Fund
£696.4k - Industry AVG
Growth
3 year (CAGR) sales growth of -2%, show it is growing at a slower rate (8.1%)
-2% - June Hancock Mesothelioma Research Fund
8.1% - Industry AVG
Production
with a gross margin of 38.8%, this company has a comparable cost of product (38.8%)
38.8% - June Hancock Mesothelioma Research Fund
38.8% - Industry AVG
Profitability
an operating margin of 89.5% make it more profitable than the average company (5.5%)
89.5% - June Hancock Mesothelioma Research Fund
5.5% - Industry AVG
Employees
with 1 employees, this is below the industry average (17)
1 - June Hancock Mesothelioma Research Fund
17 - Industry AVG
Pay Structure
There is insufficient data available for this Key Performance Indicator!
- - June Hancock Mesothelioma Research Fund
- - Industry AVG
Efficiency
resulting in sales per employee of £49.1k, this is equally as efficient (£49.4k)
£49.1k - June Hancock Mesothelioma Research Fund
£49.4k - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- - June Hancock Mesothelioma Research Fund
- - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- - June Hancock Mesothelioma Research Fund
- - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - June Hancock Mesothelioma Research Fund
- - Industry AVG
Cash Balance
has cash to cover current liabilities
for 100 weeks, this is average cash available to meet short term requirements (106 weeks)
100 weeks - June Hancock Mesothelioma Research Fund
106 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 47.4%, this is a higher level of debt than the average (25.7%)
47.4% - June Hancock Mesothelioma Research Fund
25.7% - Industry AVG
JUNE HANCOCK MESOTHELIOMA RESEARCH FUND financials
EXPORT
June Hancock Mesothelioma Research Fund's latest turnover from June 2024 is £49.1 thousand and the company has net assets of £278.7 thousand. According to their latest financial statements, we estimate that June Hancock Mesothelioma Research Fund has 1 employee and maintains cash reserves of £345.4 thousand as reported in the balance sheet.
Data source:Companies House, Pomanda Estimates
Jun 2024
Jun 2023
Jun 2022
Jun 2021
Jun 2020
Jun 2019
Jun 2018
Jun 2017
Jun 2016
Jun 2015
Jun 2014
Jun 2013
Jun 2012
Jun 2011
Jun 2010
Turnover
49,099
46,420
93,701
52,645
285,753
176,605
82,315
68,644
89,161
117,147
108,709
192,636
108,767
201,761
157,388
Other Income Or Grants
Cost Of Sales
30,069
28,491
58,656
34,895
182,407
113,615
52,920
42,111
55,415
73,606
67,468
116,996
62,851
114,593
87,903
Gross Profit
19,030
17,929
35,045
17,750
103,346
62,990
29,395
26,533
33,746
43,541
41,241
75,640
45,916
87,168
69,485
Admin Expenses
-24,894
608,416
-1,098
-44,330
-249,578
-54,348
32,925
-66,047
-56,222
369,411
-36,022
-92,006
134,882
-175,079
105,016
Operating Profit
43,924
-590,487
36,143
62,080
352,924
117,338
-3,530
92,580
89,968
-325,870
77,263
167,646
-88,966
262,247
-35,531
Interest Payable
Interest Receivable
Pre-Tax Profit
50,960
-557,708
36,475
50,816
286,294
97,223
-2,094
75,597
73,414
-323,535
63,011
130,888
-86,688
195,507
-34,671
Tax
Profit After Tax
50,960
-557,708
36,475
50,816
286,294
97,223
-2,094
75,597
73,414
-323,535
63,011
130,888
-86,688
195,507
-34,671
Dividends Paid
Retained Profit
50,960
-557,708
36,475
50,816
286,294
97,223
-2,094
75,597
73,414
-323,535
63,011
130,888
-86,688
195,507
-34,671
Employee Costs
156
321
221
65,353
173
120
158
Number Of Employees
1
1
3
2
7
6
6
6
6
3
6
6
6
6
6
EBITDA*
43,924
-590,487
36,143
62,080
352,924
117,338
-3,530
92,580
89,968
-325,870
77,263
167,646
-88,966
262,247
-35,531
* Earnings Before Interest, Tax, Depreciation and Amortisation
Jun 2024
Jun 2023
Jun 2022
Jun 2021
Jun 2020
Jun 2019
Jun 2018
Jun 2017
Jun 2016
Jun 2015
Jun 2014
Jun 2013
Jun 2012
Jun 2011
Jun 2010
Tangible Assets
Intangible Assets
Investments & Other
183,164
173,814
Debtors (Due After 1 year)
Total Fixed Assets
183,164
173,814
Stock & work in progress
Trade Debtors
Group Debtors
Misc Debtors
1,105
882
443
537
1,440
36
36
971
1,135
129
1,130
2,524
Cash
345,434
569,730
741,425
680,669
631,773
418,740
298,761
275,693
324,148
395,694
538,313
460,681
474,675
436,630
343,886
misc current assets
60,264
70,131
67,708
64,189
61,209
61,001
58,044
54,830
51,477
51,841
total current assets
346,539
570,612
801,689
750,800
699,924
482,929
360,507
338,134
382,228
450,560
590,761
513,657
474,804
437,760
346,410
total assets
529,703
744,426
801,689
750,800
699,924
482,929
360,507
338,134
382,228
450,560
590,761
513,657
474,804
437,760
346,410
Bank overdraft
Bank loan
Trade Creditors
Group/Directors Accounts
other short term finances
hp & lease commitments
other current liabilities
179,449
216,943
16,274
1,860
1,800
71,099
30,900
21,433
4,720
137,209
76,229
76,186
106,241
26,769
87,669
total current liabilities
179,449
216,943
16,274
1,860
1,800
71,099
30,900
21,433
4,720
137,209
76,229
76,186
106,241
26,769
87,669
loans
hp & lease commitments
Accruals and Deferred Income
other liabilities
71,587
299,776
15,000
136,404
136,404
14,050
61,980
17,720
60,977
provisions
total long term liabilities
71,587
299,776
15,000
136,404
136,404
14,050
61,980
17,720
60,977
total liabilities
251,036
516,719
16,274
1,860
1,800
71,099
45,900
21,433
141,124
273,613
90,279
76,186
168,221
44,489
148,646
net assets
278,667
227,707
785,415
748,940
698,124
411,830
314,607
316,701
241,104
176,947
500,482
437,471
306,583
393,271
197,764
total shareholders funds
278,667
227,707
785,415
748,940
698,124
411,830
314,607
316,701
241,104
176,947
500,482
437,471
306,583
393,271
197,764
Jun 2024
Jun 2023
Jun 2022
Jun 2021
Jun 2020
Jun 2019
Jun 2018
Jun 2017
Jun 2016
Jun 2015
Jun 2014
Jun 2013
Jun 2012
Jun 2011
Jun 2010
Operating Activities
Operating Profit
43,924
-590,487
36,143
62,080
352,924
117,338
-3,530
92,580
89,968
-325,870
77,263
167,646
-88,966
262,247
-35,531
Depreciation
Amortisation
Tax
Stock
Debtors
223
882
-443
443
-537
-903
1,404
-935
-164
1,006
-1,001
-1,394
2,524
Creditors
Accruals and Deferred Income
-37,494
200,669
14,414
60
-69,299
40,199
9,467
16,713
-132,489
60,980
43
-30,055
79,472
-60,900
87,669
Deferred Taxes & Provisions
Cash flow from operations
6,207
-390,700
50,557
62,583
283,182
158,074
6,840
107,889
-42,521
-263,955
77,470
136,585
-8,493
202,741
49,614
Investing Activities
capital expenditure
Change in Investments
9,350
173,814
cash flow from investments
-9,350
-173,814
Financing Activities
Bank loans
Group/Directors Accounts
Other Short Term Loans
Long term loans
Hire Purchase and Lease Commitments
other long term liabilities
-228,189
299,776
-15,000
15,000
-136,404
122,354
14,050
-61,980
44,260
-43,257
60,977
share issue
-9,257
232,435
interest
cash flow from financing
-228,189
299,776
-15,000
15,000
-136,404
-9,257
122,354
14,050
-61,980
44,260
-43,257
293,412
cash and cash equivalents
cash
-224,296
-171,695
60,756
48,896
213,033
119,979
23,068
-48,455
-71,546
-142,619
77,632
-13,994
38,045
92,744
343,886
overdraft
change in cash
-224,296
-171,695
60,756
48,896
213,033
119,979
23,068
-48,455
-71,546
-142,619
77,632
-13,994
38,045
92,744
343,886
june hancock mesothelioma research fund Credit Report and Business Information
Very Low Risk70 - 100
Low Risk50 - 70
Moderate Risk30 - 50
High Risk20 - 30
Very High Risk0 - 20
Get a comprehensive credit check for june hancock mesothelioma research fund. Get real-time insights into june hancock mesothelioma research fund's credit score, group structure and payment trends.
June Hancock Mesothelioma Research Fund Competitor Analysis
Perform a competitor analysis for june hancock mesothelioma research fund by selecting its closest rivals, whether from the HUMAN HEALTH AND SOCIAL WORK ACTIVITIES sector, other micro companies, companies in S 3 area or any other competitors across 12 key performance metrics.
june hancock mesothelioma research fund Ownership
JUNE HANCOCK MESOTHELIOMA RESEARCH FUND group structure
June Hancock Mesothelioma Research Fund has no subsidiary companies.
Ultimate parent company
JUNE HANCOCK MESOTHELIOMA RESEARCH FUND
06249601
JUNE HANCOCK MESOTHELIOMA RESEARCH FUND Shareholders
The sole shareholder of June Hancock Mesothelioma Research Fund is -.
-
-
june hancock mesothelioma research fund directors
June Hancock Mesothelioma Research Fund currently has 6 directors.
The longest serving directors include
Mr Adrian Budgen (May 2007) and
Mr Adrian Budgen (May 2007).
june hancock mesothelioma research fund company details
company number
06249601
Type
Private Limited by guarantee without Share Capital Exempt from using Limited
industry
86900 - Other human health activities
incorporation date
May 2007
age
18
incorporated
UK
ultimate parent company
None
accounts
Total Exemption Full
last accounts submitted
June 2024
previous names
N/A
accountant
TOM HENSHAW
auditor
-
address
riverside east, 2 millsands, sheffield, S3 8DT
Bank
C A F CASH
Legal Advisor
-
june hancock mesothelioma research fund Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to june hancock mesothelioma research fund.
june hancock mesothelioma research fund Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for JUNE HANCOCK MESOTHELIOMA RESEARCH FUND. This can take several minutes, an email will notify you when this has completed.
june hancock mesothelioma research fundCompanies House Filings - See Documents
